Sovaldi: Shooting Star Rather Than Blockbuster?
This article was originally published in PharmAsia News
Executive Summary
Gilead’s hepatitis C virus (HCV) treatment has earned a special place in pharma lore with its rapid rise to about $10 billion in annual sales, bringing with it lots of controversy about the sustainability of specialty drug pricing. Now the product appears poised to make a new reputation: fastest to fall from blockbuster status.
You may also be interested in...
Harvoni Cost Will Be Roughly Equal To Sovaldi For Most HCV Patients (Updated)
Sovaldi/ledipasvir combo pill – the first one-tablet, oral hepatitis C option in the U.S. – was approved Oct. 10 with a price of $94,500 for a 12-week course of therapy, similar to the cost of Sovaldi plus interferon and ribavirin. Insurers group says Gilead “seems to believe it has a blank check.”
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.
As Sickle Cell Gene Therapies Move To Market, Health Inequities Could Help Pricing Debate
Positive tandem ICER reviews for bluebird bio’s and Vertex/CRISPR’s gene therapies show the impact that concerns about addressing racial inequities could create a favorable context for products as they enter pricing and coverage discussions.